In vitro susceptibility of Clostridium difficile clinical isolates from a multi-institutional outbreak in Southern Québec, Canada
- PMID: 17005836
- PMCID: PMC1610058
- DOI: 10.1128/AAC.00479-06
In vitro susceptibility of Clostridium difficile clinical isolates from a multi-institutional outbreak in Southern Québec, Canada
Abstract
Clostridium difficile isolates from a 2004 outbreak in Québec, Canada, were all found to be susceptible to metronidazole, vancomycin, rifampin, and meropenem but resistant to bacitracin, cefotaxime, ciprofloxacin, and levofloxacin, and most (>80%) were resistant to ceftriaxone, clarithromycin, gatifloxacin, and moxifloxacin. The predominant NAP1 isolates were susceptible to clindamycin, while the NAP2 isolates were resistant.
References
-
- Barbut, F., G. Corthier, and Y. Charpak. 1996. Prevalence and pathogenicity of Clostridium difficile in hospitalized patients: a French multicenter study. Arch. Intern. Med. 156:1449-1454. - PubMed
-
- Bartlett, J. G., and T. M. Perl. 2005. The new Clostridium difficile—what does it mean? N. Engl. J. Med. 353:2503-2505. - PubMed
-
- Contant, C., D. Olden, J. Bell, and J. D. Turnidge. 1996. Disk diffusion interpretive criteria for fusidic acid susceptibility for testing of staphylococci by the National Committee for Clinical Laboratory Standards method. Diagn. Microbiol. Infect. Dis. 25:9-13. - PubMed
-
- Freeman, J., and M. H. Wilcox. 2001. Antibiotic activity against genotypically distinct and indistinguishable Clostridium difficile isolates. J. Antimicrob. Chemother. 47:244-246. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
